Alpha Cognition Inc. (ACOG)
NASDAQ: ACOG · Real-Time Price · USD
6.01
-0.06 (-0.91%)
Jan 22, 2025, 1:09 PM EST - Market open
Company Description
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury.
It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.
The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021.
Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Alpha Cognition Inc.
| Country | Canada |
| Founded | 2000 |
| CEO | Michael McFadden |
Contact Details
Address: 750 West Pender Street, Suite 1200 Vancouver, BC V6C 2T8 Canada | |
| Phone | 858 344 4375 |
| Website | alphacognition.com |
Stock Details
| Ticker Symbol | ACOG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001655923 |
| ISIN Number | CA02074J5017 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael McFadden | Chief Executive Officer |
| Henry Du | Chief Financial Officer |
| Lauren D’Angelo | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 15, 2025 | 424B3 | Prospectus |
| Jan 15, 2025 | 424B3 | Prospectus |
| Jan 13, 2025 | EFFECT | Notice of Effectiveness |
| Jan 13, 2025 | EFFECT | Notice of Effectiveness |
| Jan 10, 2025 | POS AM | Post-Effective amendments for registration statement |
| Jan 10, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Dec 31, 2024 | POS AM | Post-Effective amendments for registration statement |
| Dec 31, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 31, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 20, 2024 | 8-K | Current Report |